Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 1
1992 1
1995 1
1999 1
2000 3
2002 1
2003 3
2004 3
2005 2
2006 1
2007 3
2008 5
2009 7
2010 5
2011 3
2012 8
2013 4
2014 4
2015 5
2016 6
2017 4
2018 11
2019 7
2020 15
2021 13
2022 7
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Benjamin R, et al. Among authors: jozwik a. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. Lancet. 2020. PMID: 33308471 Clinical Trial.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Among authors: jozwik a. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
Emerging Cellular Therapies: T Cells and Beyond.
Todryk S, Jozwik A, de Havilland J, Hester J. Todryk S, et al. Among authors: jozwik a. Cells. 2019 Mar 26;8(3):284. doi: 10.3390/cells8030284. Cells. 2019. PMID: 30917514 Free PMC article.
The current use and evolving landscape of nutraceuticals.
Chopra AS, Lordan R, Horbańczuk OK, Atanasov AG, Chopra I, Horbańczuk JO, Jóźwik A, Huang L, Pirgozliev V, Banach M, Battino M, Arkells N. Chopra AS, et al. Among authors: jozwik a. Pharmacol Res. 2022 Jan;175:106001. doi: 10.1016/j.phrs.2021.106001. Epub 2021 Nov 24. Pharmacol Res. 2022. PMID: 34826602 Review.
Allogeneic CAR-T Cells: More than Ease of Access?
Graham C, Jozwik A, Pepper A, Benjamin R. Graham C, et al. Among authors: jozwik a. Cells. 2018 Oct 1;7(10):155. doi: 10.3390/cells7100155. Cells. 2018. PMID: 30275435 Free PMC article. Review.
Phytol: A review of biomedical activities.
Islam MT, Ali ES, Uddin SJ, Shaw S, Islam MA, Ahmed MI, Chandra Shill M, Karmakar UK, Yarla NS, Khan IN, Billah MM, Pieczynska MD, Zengin G, Malainer C, Nicoletti F, Gulei D, Berindan-Neagoe I, Apostolov A, Banach M, Yeung AWK, El-Demerdash A, Xiao J, Dey P, Yele S, Jóźwik A, Strzałkowska N, Marchewka J, Rengasamy KRR, Horbańczuk J, Kamal MA, Mubarak MS, Mishra SK, Shilpi JA, Atanasov AG. Islam MT, et al. Among authors: jozwik a. Food Chem Toxicol. 2018 Nov;121:82-94. doi: 10.1016/j.fct.2018.08.032. Epub 2018 Aug 18. Food Chem Toxicol. 2018. PMID: 30130593
Vasculoprotective Effects of Pomegranate (Punica granatum L.).
Wang D, Özen C, Abu-Reidah IM, Chigurupati S, Patra JK, Horbanczuk JO, Jóźwik A, Tzvetkov NT, Uhrin P, Atanasov AG. Wang D, et al. Among authors: jozwik a. Front Pharmacol. 2018 May 24;9:544. doi: 10.3389/fphar.2018.00544. eCollection 2018. Front Pharmacol. 2018. PMID: 29881352 Free PMC article. Review.
Ethnopharmacological Applications Targeting Alcohol Abuse: Overview and Outlook.
Singh L, Joshi T, Tewari D, Echeverría J, Mocan A, Sah AN, Parvanov E, Tzvetkov NT, Ma ZF, Lee YY, Poznański P, Huminiecki L, Sacharczuk M, Jóźwik A, Horbańczuk JO, Feder-Kubis J, Atanasov AG. Singh L, et al. Among authors: jozwik a. Front Pharmacol. 2020 Feb 14;10:1593. doi: 10.3389/fphar.2019.01593. eCollection 2019. Front Pharmacol. 2020. PMID: 32116660 Free PMC article. Review.
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, Benjamin R, Balandraud S. Dupouy S, et al. Among authors: jozwik a. Cancer Res Commun. 2022 Nov 30;2(11):1520-1531. doi: 10.1158/2767-9764.CRC-22-0175. eCollection 2022 Nov. Cancer Res Commun. 2022. PMID: 36970059 Free PMC article.
126 results